Hims & Hers Health (NYSE:HIMS – Get Free Report) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday,Zacks.com reports.
Several other equities analysts have also issued reports on HIMS. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 5th. TD Cowen decreased their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Citigroup boosted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. decreased their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.70.
Check Out Our Latest Report on HIMS
Hims & Hers Health Price Performance
Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.20 earnings per share. On average, equities analysts anticipate that Hims & Hers Health will post 0.04 EPS for the current year.
Insiders Place Their Bets
In related news, insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the transaction, the insider directly owned 8,752 shares in the company, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David B. Wells acquired 48,400 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the transaction, the director directly owned 224,417 shares in the company, valued at $5,437,623.91. This trade represents a 27.50% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 212,807 shares of company stock worth $5,473,644 in the last three months. 11.76% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Hims & Hers Health
Institutional investors and hedge funds have recently modified their holdings of the business. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at approximately $28,000. Silicon Valley Capital Partners acquired a new position in Hims & Hers Health during the 3rd quarter worth approximately $48,000. Flagship Harbor Advisors LLC acquired a new position in Hims & Hers Health during the 4th quarter worth approximately $28,000. Bogart Wealth LLC boosted its position in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Hims & Hers Health by 44.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after acquiring an additional 283 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Read More
- Five stocks we like better than Hims & Hers Health
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
